Saichi Melissa, Ladjemi Maha Zohra, Korniotis Sarantis, Rousseau Christophe, Ait Hamou Zakaria, Massenet-Regad Lucile, Amblard Elise, Noel Floriane, Marie Yannick, Bouteiller Delphine, Medvedovic Jasna, Pène Frédéric, Soumelis Vassili
Université de Paris, INSERM U976, Paris, France.
Institut Cochin, INSERM U1016, CNRS UMR8104, Université de Paris, Paris, France.
Nat Cell Biol. 2021 May;23(5):538-551. doi: 10.1038/s41556-021-00681-2. Epub 2021 May 10.
COVID-19 can lead to life-threatening respiratory failure, with increased inflammatory mediators and viral load. Here, we perform single-cell RNA-sequencing to establish a high-resolution map of blood antigen-presenting cells (APCs) in 15 patients with moderate or severe COVID-19 pneumonia, at day 1 and day 4 post admission to intensive care unit or pulmonology department, as well as in 4 healthy donors. We generated a unique dataset of 81,643 APCs, including monocytes and rare dendritic cell (DC) subsets. We uncovered multi-process defects in antiviral immune defence in specific APCs from patients with severe disease: (1) increased pro-apoptotic pathways in plasmacytoid DCs (pDCs, key effectors of antiviral immunity), (2) a decrease of the innate sensors TLR9 and DHX36 in pDCs and CLEC9a DCs, respectively, (3) downregulation of antiviral interferon-stimulated genes in monocyte subsets and (4) a decrease of major histocompatibility complex (MHC) class II-related genes and MHC class II transactivator activity in cDC1c DCs, suggesting viral inhibition of antigen presentation. These novel mechanisms may explain patient aggravation and suggest strategies to restore the defective immune defence.
新冠病毒病(COVID-19)可导致危及生命的呼吸衰竭,同时炎症介质和病毒载量增加。在此,我们进行了单细胞RNA测序,以建立15例中度或重度COVID-19肺炎患者在入住重症监护病房或肺病科后第1天和第4天以及4名健康供体血液中抗原呈递细胞(APC)的高分辨率图谱。我们生成了一个包含81,643个APC的独特数据集,其中包括单核细胞和罕见的树突状细胞(DC)亚群。我们发现重症患者特定APC的抗病毒免疫防御存在多过程缺陷:(1)浆细胞样DC(pDC,抗病毒免疫的关键效应细胞)中促凋亡途径增加;(2)pDC和CLEC9a DC中天然传感器TLR9和DHX36分别减少;(3)单核细胞亚群中抗病毒干扰素刺激基因下调;(4)cDC1c DC中主要组织相容性复合体(MHC)II类相关基因和MHC II类反式激活因子活性降低,提示病毒对抗原呈递的抑制作用。这些新机制可能解释患者病情加重的原因,并为恢复有缺陷的免疫防御提供策略。